CMS allows coverage of genomic testing to go beyond advanced cancer diagnoses
Medicare will allow providers to harness a powerful DNA sequencing technology that can rapidly monitor a patient’s genome and pinpoint harmful disease characteristics — and the applications may extend well beyond cancer.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.